BRPI0618794A2 - uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial - Google Patents
uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial Download PDFInfo
- Publication number
- BRPI0618794A2 BRPI0618794A2 BRPI0618794-3A BRPI0618794A BRPI0618794A2 BR PI0618794 A2 BRPI0618794 A2 BR PI0618794A2 BR PI0618794 A BRPI0618794 A BR PI0618794A BR PI0618794 A2 BRPI0618794 A2 BR PI0618794A2
- Authority
- BR
- Brazil
- Prior art keywords
- pdgf
- bone
- biocompatible matrix
- calcium phosphate
- allograft
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 200
- 239000011159 matrix material Substances 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 230000003416 augmentation Effects 0.000 title claims abstract description 71
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 79
- 239000012528 membrane Substances 0.000 claims abstract description 45
- 108010081589 Becaplermin Proteins 0.000 claims abstract description 42
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 27
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims abstract description 24
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims abstract description 24
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 24
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims description 47
- 102000008186 Collagen Human genes 0.000 claims description 47
- 229920001436 collagen Polymers 0.000 claims description 47
- 239000002245 particle Substances 0.000 claims description 44
- 230000007547 defect Effects 0.000 claims description 25
- 238000002513 implantation Methods 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 16
- 210000001847 jaw Anatomy 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 12
- 210000004086 maxillary sinus Anatomy 0.000 claims description 5
- 108010000685 platelet-derived growth factor AB Proteins 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000002050 maxilla Anatomy 0.000 claims description 4
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 4
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 239000000710 homodimer Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 62
- 239000007943 implant Substances 0.000 abstract description 46
- 239000000463 material Substances 0.000 abstract description 21
- 210000001909 alveolar process Anatomy 0.000 abstract description 18
- 210000004373 mandible Anatomy 0.000 abstract description 17
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 86
- 239000011230 binding agent Substances 0.000 description 50
- 239000004566 building material Substances 0.000 description 50
- 238000001356 surgical procedure Methods 0.000 description 32
- 238000011282 treatment Methods 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000004872 soft tissue Anatomy 0.000 description 12
- 239000010936 titanium Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 229910052719 titanium Inorganic materials 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 230000010478 bone regeneration Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000009969 flowable effect Effects 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000008468 bone growth Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003239 periodontal effect Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000011800 void material Substances 0.000 description 5
- 108010009565 Bio-Gide Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000004023 fresh frozen plasma Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004763 bicuspid Anatomy 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000002138 osteoinductive effect Effects 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010027258 GEM 21S Proteins 0.000 description 2
- 229920000544 Gore-Tex Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000602164 Homo sapiens Platelet-derived growth factor subunit A Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003160 anti-catabolic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003592 biomimetic effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037176 bone building Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000004035 construction material Substances 0.000 description 2
- 230000023753 dehiscence Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000020938 metabolic status Nutrition 0.000 description 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000002698 mandibular nerve Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001042 poly(δ-valerolactone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000003133 primary dentition Anatomy 0.000 description 1
- 230000005207 primary tooth eruption Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000001782 transverse sinus Anatomy 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2803—Bones for mandibular reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2846—Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Dentistry (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73807605P | 2005-11-17 | 2005-11-17 | |
| US60/738,076 | 2005-11-17 | ||
| PCT/US2006/044766 WO2007061889A2 (en) | 2005-11-17 | 2006-11-17 | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0618794A2 true BRPI0618794A2 (pt) | 2011-09-13 |
Family
ID=38067796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0618794-3A BRPI0618794A2 (pt) | 2005-11-17 | 2006-11-17 | uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8114841B2 (enExample) |
| EP (2) | EP2431060B1 (enExample) |
| JP (1) | JP5368102B2 (enExample) |
| KR (1) | KR20080084808A (enExample) |
| CN (1) | CN101370531A (enExample) |
| BR (1) | BRPI0618794A2 (enExample) |
| CA (1) | CA2630077C (enExample) |
| NO (1) | NO20082393L (enExample) |
| NZ (1) | NZ571113A (enExample) |
| WO (1) | WO2007061889A2 (enExample) |
| ZA (1) | ZA200804548B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| WO2007061889A2 (en) | 2005-11-17 | 2007-05-31 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| ES2427993T3 (es) * | 2006-02-09 | 2013-11-05 | Biomimetic Therapeutics, Llc | Composiciones y métodos para el tratamiento de hueso |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| WO2008005427A2 (en) * | 2006-06-30 | 2008-01-10 | Biomimetic Therapeutics, Inc. | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
| US9943410B2 (en) | 2011-02-28 | 2018-04-17 | DePuy Synthes Products, Inc. | Modular tissue scaffolds |
| EP2462895B1 (en) | 2006-11-03 | 2016-11-02 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| FI3345607T3 (fi) | 2006-12-29 | 2022-11-30 | Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia | |
| WO2008103690A2 (en) * | 2007-02-20 | 2008-08-28 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix |
| US20090042158A1 (en) * | 2007-08-09 | 2009-02-12 | Gregory Gene Steiner | Method for regenerating bone in the maxillary sinus |
| CA2715254A1 (en) | 2008-02-07 | 2009-08-13 | Biomimetic Therapeutics, Inc. | Compositions and methods for distraction osteogenesis |
| US9616153B2 (en) * | 2008-04-17 | 2017-04-11 | Warsaw Orthopedic, Inc. | Rigid bone graft substitute |
| CN102231992B (zh) | 2008-09-09 | 2015-05-20 | 生物模拟治疗公司 | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 |
| EP2376106A4 (en) * | 2008-12-19 | 2013-01-09 | Biomimetic Therapeutics Inc | BONE TRANSPLANTS WITH REDUCED PROTEASE EFFECT AND SELECTION AND APPLICATION PROCEDURES |
| JP2012519556A (ja) * | 2009-03-05 | 2012-08-30 | バイオミメティック セラピューティクス， インコーポレイテッド | 骨軟骨欠損を治療するための血小板由来増殖因子組成物および方法 |
| WO2011038354A1 (en) * | 2009-09-25 | 2011-03-31 | Tuffs University | Dental graft for treating periodontal conditions and thin biotypes |
| US8994666B2 (en) * | 2009-12-23 | 2015-03-31 | Colin J. Karpfinger | Tactile touch-sensing interface system |
| BR112012020566B1 (pt) * | 2010-02-22 | 2021-09-21 | Biomimetic Therapeutics, Llc | Composição de fator de crescimento derivado de plaqueta |
| AU2011329054B2 (en) | 2010-11-15 | 2015-05-28 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| WO2012082773A1 (en) * | 2010-12-13 | 2012-06-21 | Biomimetic Therapeutics, Inc. | Compositions and methods for spine fusion procedures |
| US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
| SG11201404500SA (en) * | 2012-02-01 | 2014-11-27 | Organ Technologies Inc | Dental implant and method for producing same |
| CN105085652B (zh) * | 2014-05-16 | 2021-06-22 | 中国人民解放军军事医学科学院生物工程研究所 | 血小板衍生生长因子b突变体、其制备方法及用途 |
| MX2017004520A (es) * | 2014-10-14 | 2018-03-15 | Lynch Samuel | Composiciones para tratar heridas. |
| WO2016126220A1 (en) * | 2015-02-04 | 2016-08-11 | Polat Serkan | Membrane system for forming bone without graft |
| CN105126172B (zh) * | 2015-09-28 | 2017-12-12 | 武汉大学 | 一种增高牙槽嵴的牙支架的制备及安装方法 |
| US20230120120A1 (en) * | 2016-11-18 | 2023-04-20 | Cutting Edge Technology, LLC | Pharmaceutical formulation |
| CN110236710A (zh) * | 2018-03-09 | 2019-09-17 | 中日友好医院 | 一种促进植骨材料在牙种植上颌窦外提升术后成骨的方法 |
| US12419752B2 (en) * | 2019-11-27 | 2025-09-23 | Igor Roshkovan | Surgical technique for alveolar ridge augmentation with maxillary sinus elevation (lateral approach) using a pre-portioned and ready pre-packaged bone graft composition in gelatin bag and method of producing it |
Family Cites Families (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943072A (en) * | 1971-12-15 | 1976-03-09 | United Kingdom Atomic Energy Authority | Separation of molecules |
| USRE33161E (en) * | 1982-04-29 | 1990-02-06 | American Dental Association Health Foundation | Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements |
| NL8402158A (nl) | 1983-07-09 | 1985-02-01 | Sumitomo Cement Co | Poreus keramisch materiaal en werkwijze voor de bereiding daarvan. |
| US4889919A (en) * | 1986-08-13 | 1989-12-26 | Zymogenetics, Inc. | Biologically active PDGF derived A-chain homodimers |
| US4766073A (en) * | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5187263A (en) | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| US5165938A (en) | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
| US5629191A (en) | 1985-01-03 | 1997-05-13 | Integra Lifesciences Corporation | Method of making a porous matrix particle |
| US5045633A (en) * | 1985-02-25 | 1991-09-03 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US5516896A (en) * | 1985-02-25 | 1996-05-14 | Zymogenetics, Inc. | Biologically active B-chain homodimers |
| CA1260391A (en) * | 1985-03-28 | 1989-09-26 | Karl A. Piez | Xenogeneic collagen/mineral preparations in bone repair |
| DE3530825A1 (de) * | 1985-08-29 | 1987-03-05 | Boehringer Mannheim Gmbh | Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| US5019559A (en) * | 1986-11-14 | 1991-05-28 | President And Fellows Of Harvard College | Wound healing using PDGF and IGF-II |
| US5124316A (en) | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| US4861757A (en) | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
| KR960005708B1 (ko) | 1986-11-14 | 1996-05-01 | 인스티튜트 오브 몰레큘러 바이올로지, 인코오포레이티드 | 외상 치료 및 뼈 재생용 조성물 |
| US5219759A (en) | 1987-04-22 | 1993-06-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors |
| US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US4874746A (en) | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
| US5759815A (en) | 1988-02-11 | 1998-06-02 | Creative Biomolecules, Inc. | Production of platelet derived growth factor (PDGF) an muteins thereof |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5053212A (en) * | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| US5129905A (en) * | 1988-04-20 | 1992-07-14 | Norian Corporation | Methods for in situ prepared calcium phosphate minerals |
| US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
| US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
| US5219576A (en) | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5034375A (en) * | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
| US6028105A (en) * | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
| US5035887A (en) * | 1989-09-07 | 1991-07-30 | Institute Of Moelcular Biology, Inc. | Wound healing composition of IL-1 and PDGF or IGF-1 |
| US5599558A (en) * | 1989-09-15 | 1997-02-04 | Curative Technologies, Inc. | Selecting amounts of platelet releasate for efficacious treatment of tissue |
| US5112354A (en) | 1989-11-16 | 1992-05-12 | Northwestern University | Bone allograft material and method |
| US5011910A (en) * | 1989-12-28 | 1991-04-30 | Washington University | Reagent and method for determining activity of retroviral protease |
| JP3159216B2 (ja) * | 1990-02-01 | 2001-04-23 | ユニバーシティ オブ サウス フロリダ | 白血球由来の成長因子 |
| TW199858B (enExample) | 1990-03-30 | 1993-02-11 | Fujirebio Kk | |
| DE69031218T2 (de) | 1990-04-10 | 1997-12-11 | Harvard College | Wundheilung |
| US5108322A (en) * | 1990-07-24 | 1992-04-28 | Zebco Corporation | Relay control of auxiliary functions in a trolling motor |
| US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| US5149691A (en) | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| DE4120325A1 (de) * | 1991-06-20 | 1992-12-24 | Merck Patent Gmbh | Implantatwerkstoff |
| US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| CN1104257C (zh) * | 1993-03-29 | 2003-04-02 | 津莫吉尼蒂克斯公司 | 含pdgf和维生素d的刺激成骨细胞生长的组合物 |
| AU7205894A (en) | 1993-06-08 | 1995-01-03 | Neogenix, Inc. | Purified natural and synthetic compounds for the treatment of osteoarthritis |
| US5531794A (en) | 1993-09-13 | 1996-07-02 | Asahi Kogaku Kogyo Kabushiki Kaisha | Ceramic device providing an environment for the promotion and formation of new bone |
| US5518680A (en) * | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
| JP3362267B2 (ja) * | 1993-12-29 | 2003-01-07 | 日本特殊陶業株式会社 | 生体インプラント材料及びその製造方法 |
| US5460962A (en) * | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US7963997B2 (en) | 2002-07-19 | 2011-06-21 | Kensey Nash Corporation | Device for regeneration of articular cartilage and other tissue |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5651766A (en) | 1995-06-07 | 1997-07-29 | Transfusion Technologies Corporation | Blood collection and separation system |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| US6287341B1 (en) | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US6541037B1 (en) | 1995-05-19 | 2003-04-01 | Etex Corporation | Delivery vehicle |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| DK1486565T3 (da) | 1995-10-11 | 2008-03-10 | Novartis Vaccines & Diagnostic | Kombination af PDGF, KGF, IGF og IGFBP til sårheling |
| US5783217A (en) | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
| US5747273A (en) | 1996-05-07 | 1998-05-05 | Diagnostic Systems Laboratories, Inc. | Immunoassay of total insulin-like growth factor binding protein-1 |
| CA2252860C (en) * | 1996-05-28 | 2011-03-22 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
| FR2749756B1 (fr) | 1996-06-14 | 1998-09-11 | Bioland | Procede de preparation d'un materiau composite implantable, materiau obtenu, implant comprenant ce materiau et kit de mise en oeuvre |
| US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
| ES2299183T3 (es) | 1996-10-16 | 2008-05-16 | Etex Corporation | Composiciones bioceramicas. |
| US6037519A (en) | 1997-10-20 | 2000-03-14 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions |
| DE19646782C2 (de) | 1996-11-13 | 2000-05-25 | Merck Patent Gmbh | Bioresorbierbare Polymerisationsprodukte aus strahlungshärtbaren Bindemittelsystemen |
| WO1998025963A1 (en) * | 1996-12-13 | 1998-06-18 | Chiron Corporation | Analysis and separation of platelet-derived growth factor proteins |
| US5866165A (en) * | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
| FR2758988B1 (fr) | 1997-02-05 | 2000-01-21 | S H Ind | Procede d'elaboration de substituts osseux synthetiques d'architecture poreuse parfaitement maitrisee |
| AU6267798A (en) * | 1997-02-07 | 1998-08-26 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
| WO1998038949A1 (en) | 1997-03-04 | 1998-09-11 | Implico B.V. | An artefact suitable for use as a bone implant |
| US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US20010016646A1 (en) * | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) * | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| JP3334558B2 (ja) * | 1997-04-23 | 2002-10-15 | 富士レビオ株式会社 | 酵素免疫測定方法及び試験片 |
| US20030032586A1 (en) | 1997-05-15 | 2003-02-13 | David C. Rueger | Compositions for morphogen-induced osteogenesis |
| GB2325934A (en) | 1997-06-03 | 1998-12-09 | Polybiomed Ltd | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics |
| US6063624A (en) | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
| ATE220564T1 (de) | 1997-08-14 | 2002-08-15 | Sulzer Innotec Ag | Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren |
| US6136029A (en) | 1997-10-01 | 2000-10-24 | Phillips-Origen Ceramic Technology, Llc | Bone substitute materials |
| US6090998A (en) * | 1997-10-27 | 2000-07-18 | University Of Florida | Segmentally demineralized bone implant |
| US20020018796A1 (en) | 1998-01-28 | 2002-02-14 | John F. Wironen | Thermally sterilized bone paste |
| ES2198067T3 (es) | 1998-07-28 | 2004-01-16 | Synthes Ag Chur | Utilizacion de compuestos a base de creatina para tratar las celulas y los tejidos oseos y cartilaginosos. |
| US20030114936A1 (en) | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
| US6224635B1 (en) * | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
| US6663870B2 (en) | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
| US6231528B1 (en) | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
| EP1025871A1 (en) | 1999-01-28 | 2000-08-09 | F. Hoffmann-La Roche Ag | Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair |
| ATE253385T1 (de) | 1999-02-04 | 2003-11-15 | Sdgi Holdings Inc | Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung |
| US6294187B1 (en) * | 1999-02-23 | 2001-09-25 | Osteotech, Inc. | Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same |
| ATE318625T1 (de) | 1999-03-15 | 2006-03-15 | Implant Innovations Inc | Sammelsystem für thrombozyten |
| US6296602B1 (en) * | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
| CA2370063C (en) | 1999-03-19 | 2012-10-02 | The Regents Of The University Of Michigan | Mineralization and cellular patterning on biomaterial surfaces |
| WO2000061256A1 (en) * | 1999-04-12 | 2000-10-19 | Harvest Technologies Corporation | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
| SE515227C2 (sv) | 1999-04-28 | 2001-07-02 | Bruce Medical Ab | Kropp för åstadkommande av in- och tillväxt av benvävnad och/ eller bindväv och sätt för framställning av kroppen |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| US6710025B1 (en) | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
| US6312952B1 (en) | 1999-05-27 | 2001-11-06 | The Research Foundation Of State University Of New York | In vitro cell culture device including cartilage and methods of using the same |
| DE19926083A1 (de) | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biologisches Gelenkkonstrukt |
| US6429013B1 (en) * | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
| DE19940717A1 (de) | 1999-08-26 | 2001-03-01 | Gerontocare Gmbh | Resorblerbares Knochenersatz- und Knochenaufbaumaterial |
| US6280191B1 (en) * | 1999-09-03 | 2001-08-28 | Christopher B. Gordon | Distractor suitable for permanent implantation into bone |
| JP4809963B2 (ja) * | 1999-11-11 | 2011-11-09 | オリンパス株式会社 | 骨補填材 |
| US6451059B1 (en) | 1999-11-12 | 2002-09-17 | Ethicon, Inc. | Viscous suspension spinning process for producing resorbable ceramic fibers and scaffolds |
| DE60003459T2 (de) | 1999-12-09 | 2004-05-06 | Biosyntech Canada Inc., Laval | Mineral-polymer hybrid-zusammensetzung |
| CA2328818A1 (en) | 1999-12-16 | 2001-06-16 | Isotis B.V. | Porous ceramic body |
| US20030103960A1 (en) * | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
| JP2003518411A (ja) * | 1999-12-29 | 2003-06-10 | リジェネレーション テクノロジーズ インク． | ペースト再構成のためのシステムおよびその使用法 |
| AU4234901A (en) | 2000-01-28 | 2001-08-07 | Dot Dunnschicht Und Oberflache | Inorganic resorbable bone substitute material and production method |
| AU2000251259A1 (en) | 2000-02-04 | 2001-08-14 | Zymogenetics Inc. | Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| IT1316769B1 (it) * | 2000-02-18 | 2003-05-12 | Getters Spa | Pannello evacuato per isolamento termico con ridotta conduzione dicalore ai bordi |
| JP2003535620A (ja) | 2000-02-18 | 2003-12-02 | リジェネレーション テクノロジーズ インク． | 増殖因子および他の添加物を注入した移植用組織 |
| US7022506B2 (en) * | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
| JP2003525696A (ja) * | 2000-03-03 | 2003-09-02 | スミス アンド ネフュー インコーポレーテッド | 造形粒子および骨欠損用組成物および粒子を作る方法 |
| US20030055511A1 (en) | 2000-03-03 | 2003-03-20 | Schryver Jeffrey E. | Shaped particle comprised of bone material and method of making the particle |
| AU784377B2 (en) * | 2000-03-14 | 2006-03-23 | Arthur V. Sampaio | Compositions and methods for affecting osteogenesis |
| US20020006437A1 (en) | 2000-05-01 | 2002-01-17 | Grooms Jamie M. | Non-migration tissue capsule |
| EP1287506A2 (en) * | 2000-05-19 | 2003-03-05 | Europrint Holdings Limited | Method and system for implementing a game |
| US20020022885A1 (en) | 2000-05-19 | 2002-02-21 | Takahiro Ochi | Biomaterial |
| DK1294414T3 (da) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv |
| DK177997B1 (da) | 2000-07-19 | 2015-02-23 | Ed Geistlich Söhne Ag Für Chemische Ind | Knoglemateriale og collagenkombination til opheling af beskadigede led |
| GB0020610D0 (en) | 2000-08-21 | 2000-10-11 | Dytech Corp Ltd | Uses of porous carriers |
| US6739112B1 (en) * | 2000-08-21 | 2004-05-25 | Nu Vasive, Inc. | Bone allograft packaging system |
| US6773723B1 (en) | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
| EP1337266A4 (en) | 2000-10-31 | 2006-11-02 | Depuy Spine Inc | MINERALIZED COLLAGEN POLYSACCHARIDE MATRIX FOR THE RECONSTRUCTION OF BONES AND CARTILES |
| US20020127265A1 (en) | 2000-12-21 | 2002-09-12 | Bowman Steven M. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| CA2365376C (en) * | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US7192604B2 (en) | 2000-12-22 | 2007-03-20 | Ethicon, Inc. | Implantable biodegradable devices for musculoskeletal repair or regeneration |
| JP2004533276A (ja) | 2001-01-25 | 2004-11-04 | リジェネレーション テクノロジーズ インク． | 注射可能な多孔性骨グラフト材料 |
| US7005135B2 (en) * | 2001-01-30 | 2006-02-28 | Ethicon Inc. | Glass scaffolds with controlled resorption rates and methods for making same |
| KR100877484B1 (ko) * | 2001-02-22 | 2009-01-12 | 파나소닉 주식회사 | 광 디스크 장치 |
| CA2438934A1 (en) | 2001-02-23 | 2002-09-06 | Wyeth | Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp |
| US6575986B2 (en) | 2001-02-26 | 2003-06-10 | Ethicon, Inc. | Scaffold fixation device for use in articular cartilage repair |
| US6743232B2 (en) * | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US20030049328A1 (en) | 2001-03-02 | 2003-03-13 | Dalal Paresh S. | Porous beta-tricalcium phosphate granules and methods for producing same |
| JP2003010310A (ja) * | 2001-06-27 | 2003-01-14 | Olympus Optical Co Ltd | 頭蓋骨用骨補填材料および補填方法 |
| US20030109537A1 (en) * | 2001-07-09 | 2003-06-12 | Turner Russell T. | Methods and materials for treating bone conditions |
| WO2003026714A1 (en) | 2001-09-24 | 2003-04-03 | Millenium Biologix, Inc. | Porous ceramic composite bone grafts |
| ATE384783T1 (de) | 2001-10-19 | 2008-02-15 | Zymogenetics Inc | Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung |
| US6649072B2 (en) | 2001-11-16 | 2003-11-18 | Robert Brandt | Method for producing autologous platelet-rich plasma |
| WO2003043576A2 (en) | 2001-11-20 | 2003-05-30 | Depuy Products, Inc. | Flowable osteogenic and chondrogenic compositions |
| WO2003055418A1 (en) | 2001-12-21 | 2003-07-10 | Lagow Richard J | Calcium phosphate bone replacement materials and methods of use thereof |
| AU2003210996A1 (en) | 2002-02-11 | 2003-09-04 | Zymogenetics, Inc. | Materials and methods for preparing dimeric growth factors |
| US7879107B2 (en) * | 2002-02-20 | 2011-02-01 | The Cleveland Clinic Foundation | Composition and method for inducing bone growth and healing |
| JP3739715B2 (ja) * | 2002-03-19 | 2006-01-25 | オリンパス株式会社 | 人工骨および組織工学用担体 |
| KR100460685B1 (ko) | 2002-04-10 | 2004-12-09 | 재단법인서울대학교산학협력재단 | 인산칼슘계 화합물을 이용한 인공 골 충진재 및 그 제조방법 |
| WO2003089022A1 (en) | 2002-04-18 | 2003-10-30 | University Of Florida | Biomimetic organic/inorganic composites, processes for their production, and methods of use |
| EP1539185A4 (en) * | 2002-05-02 | 2006-04-05 | Osteoscreen Inc | METHODS AND COMPOSITIONS FOR STIMULATING BONE GROWTH USING NITRIC OXIDE FREEZING BISPHOSPHONATE CONJUGATES |
| WO2003094617A2 (en) * | 2002-05-06 | 2003-11-20 | Genentech, Inc. | Use of vegf for treating bone defects |
| US7368125B2 (en) | 2002-06-05 | 2008-05-06 | Ethicon, Inc. | Amphiphilic polymers for medical applications |
| US7041309B2 (en) | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
| CA2432583A1 (en) | 2002-06-20 | 2003-12-20 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Method of preparing alpha- and beta-tricalcium phosphate powders |
| US20040002770A1 (en) | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
| DE60300666T2 (de) * | 2002-07-11 | 2006-04-27 | Biomet Deutschland Gmbh | Verfahren zur Herstellung poröser Calciumphosphatstückchen und -granulaten aus der Gelatineverarbeitung |
| DE10240083A1 (de) * | 2002-08-30 | 2004-03-11 | Austriamicrosystems Ag | Verfahren zur Kalibrierung einer Fotodiode, Halbleiterchip und Betriebsverfahren |
| US7744651B2 (en) * | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
| WO2004032965A1 (ja) | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | 内因性修復因子産生促進剤 |
| US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
| US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
| ES2269973T3 (es) * | 2003-02-13 | 2007-04-01 | Synthes Ag Chur | Mezcla inyectable para sustituir un tejido oseo. |
| MXPA05008653A (es) | 2003-02-14 | 2006-04-27 | Depuy Spine Inc | Dispositivo de fusion intervertebral formado in situ. |
| US8027050B2 (en) * | 2003-02-26 | 2011-09-27 | Science Park Corporation | Computer containing a print control program, the program, and program recording medium |
| US20040243133A1 (en) | 2003-03-05 | 2004-12-02 | Therics, Inc. | Method and system for manufacturing biomedical articles, such as using biomedically compatible infiltrant metal alloys in porous matrices |
| US20040193270A1 (en) | 2003-03-31 | 2004-09-30 | Depuyacromed, Inc. | Implantable bone graft |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| EP1638486A4 (en) | 2003-06-11 | 2010-09-29 | Osteotech Inc | OSTEOIMPLANTATES AND METHOD FOR THE PRODUCTION THEREOF |
| US6974862B2 (en) | 2003-06-20 | 2005-12-13 | Kensey Nash Corporation | High density fibrous polymers suitable for implant |
| ATE396669T1 (de) | 2003-06-24 | 2008-06-15 | Robert Mathys Foundation Dr H | Prothesenvorrichtung zur wiederherstellung von knorpel |
| DE10328892A1 (de) | 2003-06-26 | 2005-05-12 | Curasan Ag | Knochenaufbaumittel und Herstellungsverfahren |
| CA2530421C (en) | 2003-06-27 | 2015-04-21 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
| FI20031120A0 (fi) | 2003-07-31 | 2003-07-31 | Bci Bioabsorbable Concepts Ltd | Monifunktionaalinen implanttilaite |
| US7163920B2 (en) * | 2003-09-30 | 2007-01-16 | Ethicon, Inc. | Peptide with osteogenic activity |
| CU23352A1 (es) | 2003-10-16 | 2009-03-16 | Centro Nacional De Investigaciones Cientificas | Biomateriales compuestos para implantes óseos |
| ES2522575T3 (es) | 2003-10-22 | 2014-11-17 | Encelle, Inc. | Composiciones de hidrogel bioactivo para la regeneración del tejido conjuntivo |
| US20050098915A1 (en) * | 2003-11-07 | 2005-05-12 | Smith & Nephew Inc. | Manufacture of bone graft substitutes |
| CA2545860A1 (en) * | 2003-11-14 | 2005-06-02 | The Trustees Of The University Of Pennsylvania | Device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| EP1537839A1 (en) | 2003-12-02 | 2005-06-08 | Dr. h. c. Robert Mathys Foundation | Prosthetic device for cartilage repair |
| WO2005067942A1 (en) * | 2004-01-16 | 2005-07-28 | Institute Of Nutraceutical Research Pty Ltd | Glycosaminoglycan peptides derived from connective tissues and use thereof in the prevention of arthritis and other degenerative medical conditions |
| NZ579516A (en) | 2004-01-27 | 2011-01-28 | Osteotech Inc | Stabilized bone graft |
| US7189263B2 (en) * | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
| US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
| US7671012B2 (en) * | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| US7928059B2 (en) | 2004-02-24 | 2011-04-19 | Wisconsin Alumni Research Foundation | Use of neuropeptides for traumatic cartilage injury |
| KR101013999B1 (ko) | 2004-03-19 | 2011-02-14 | 재단법인서울대학교산학협력재단 | 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트 |
| US20070190101A1 (en) | 2004-03-31 | 2007-08-16 | Chunlin Yang | Flowable bone grafts |
| WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
| CN101060821A (zh) | 2004-09-21 | 2007-10-24 | 麻省理工学院 | 梯度支架及其制备方法 |
| US7390489B2 (en) * | 2004-10-08 | 2008-06-24 | Komed Co., Ltd. | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
| WO2006050493A2 (en) | 2004-11-03 | 2006-05-11 | The Regents Of The University Of Michigan | Biodegradable implant for intertransverse process fusion |
| US20060149392A1 (en) * | 2004-12-07 | 2006-07-06 | Kuo-Huang Hsieh | Biomaterials for guided tissue regeneration and drug delivery |
| US20060151383A1 (en) | 2005-01-12 | 2006-07-13 | Aaf-Mcquay Inc. | Pleated corrugated media and method of making |
| US7621963B2 (en) | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
| CA2654446C (en) | 2005-06-07 | 2014-02-25 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| WO2007061889A2 (en) | 2005-11-17 | 2007-05-31 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| US7749555B2 (en) | 2006-01-25 | 2010-07-06 | Medtronic, Inc | Modification of chemical forces of bone constructs |
| WO2007090102A2 (en) | 2006-01-27 | 2007-08-09 | The Regents Of The University Of California | Biomimetic scaffolds |
| US20070178159A1 (en) | 2006-01-30 | 2007-08-02 | Alza Corporation | In-Situ Forming Porous Scaffold |
| ES2427993T3 (es) * | 2006-02-09 | 2013-11-05 | Biomimetic Therapeutics, Llc | Composiciones y métodos para el tratamiento de hueso |
| US7833270B2 (en) | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
| WO2007133451A1 (en) | 2006-05-08 | 2007-11-22 | Nuvasive, Inc. | Cancellous bone treated with collegenase and essentially free of blood cells |
| WO2008005427A2 (en) | 2006-06-30 | 2008-01-10 | Biomimetic Therapeutics, Inc. | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| EP2462895B1 (en) | 2006-11-03 | 2016-11-02 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
| WO2008100442A1 (en) * | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
| WO2008103690A2 (en) | 2007-02-20 | 2008-08-28 | Biomimetic Therapeutics, Inc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix |
| CA2689986C (en) | 2007-06-04 | 2020-04-07 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating the vertebral column |
| AU2008265850B2 (en) * | 2007-06-15 | 2014-06-26 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| CN104623669A (zh) * | 2007-08-22 | 2015-05-20 | 斯丹姆涅恩有限公司 | 含细胞因子溶液的新组合物 |
| US7993679B2 (en) | 2007-09-25 | 2011-08-09 | Integra Lifesciences Corporation | Flowable wound matrix and its preparation and use |
| CA2715254A1 (en) * | 2008-02-07 | 2009-08-13 | Biomimetic Therapeutics, Inc. | Compositions and methods for distraction osteogenesis |
| CN102231992B (zh) | 2008-09-09 | 2015-05-20 | 生物模拟治疗公司 | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 |
| EP2376106A4 (en) | 2008-12-19 | 2013-01-09 | Biomimetic Therapeutics Inc | BONE TRANSPLANTS WITH REDUCED PROTEASE EFFECT AND SELECTION AND APPLICATION PROCEDURES |
| JP2012519556A (ja) | 2009-03-05 | 2012-08-30 | バイオミメティック セラピューティクス， インコーポレイテッド | 骨軟骨欠損を治療するための血小板由来増殖因子組成物および方法 |
-
2006
- 2006-11-17 WO PCT/US2006/044766 patent/WO2007061889A2/en not_active Ceased
- 2006-11-17 KR KR1020087014535A patent/KR20080084808A/ko not_active Ceased
- 2006-11-17 CA CA2630077A patent/CA2630077C/en active Active
- 2006-11-17 EP EP11165354.9A patent/EP2431060B1/en active Active
- 2006-11-17 BR BRPI0618794-3A patent/BRPI0618794A2/pt not_active IP Right Cessation
- 2006-11-17 NZ NZ571113A patent/NZ571113A/en not_active IP Right Cessation
- 2006-11-17 US US11/601,376 patent/US8114841B2/en active Active
- 2006-11-17 JP JP2008541379A patent/JP5368102B2/ja not_active Expired - Fee Related
- 2006-11-17 EP EP06837973A patent/EP1951327A2/en not_active Withdrawn
- 2006-11-17 CN CNA2006800511547A patent/CN101370531A/zh active Pending
-
2008
- 2008-05-26 ZA ZA2008/04548A patent/ZA200804548B/en unknown
- 2008-05-27 NO NO20082393A patent/NO20082393L/no not_active Application Discontinuation
-
2012
- 2012-01-05 US US13/344,506 patent/US20120128774A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1951327A2 (en) | 2008-08-06 |
| CN101370531A (zh) | 2009-02-18 |
| US20070129807A1 (en) | 2007-06-07 |
| US20120128774A1 (en) | 2012-05-24 |
| ZA200804548B (en) | 2012-02-29 |
| JP5368102B2 (ja) | 2013-12-18 |
| EP2431060B1 (en) | 2020-04-08 |
| NZ571113A (en) | 2012-02-24 |
| US8114841B2 (en) | 2012-02-14 |
| NO20082393L (no) | 2008-08-15 |
| EP2431060A3 (en) | 2012-07-25 |
| CA2630077C (en) | 2014-07-15 |
| EP2431060A2 (en) | 2012-03-21 |
| JP2009515668A (ja) | 2009-04-16 |
| KR20080084808A (ko) | 2008-09-19 |
| WO2007061889A3 (en) | 2008-02-21 |
| CA2630077A1 (en) | 2007-05-31 |
| AU2006318689A1 (en) | 2007-05-31 |
| WO2007061889A2 (en) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8114841B2 (en) | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix | |
| Lee et al. | The bone regenerative effect of platelet‐derived growth factor‐BB delivered with a chitosan/tricalcium phosphate sponge carrier | |
| Von Arx et al. | Membrane durability and tissue response of different bioresorbable barrier membranes: a histologic study in the rabbit calvarium. | |
| Brkovic et al. | Simple preservation of a maxillary extraction socket using beta-tricalcium phosphate with type I collagen: preliminary clinical and histomorphometric observations. | |
| US9757213B2 (en) | Hybrid dental implant | |
| BRPI0516105B1 (pt) | material de implante consistindo em fosfato de cálcio poroso ou colágeno e fosfato de cálcio poroso, material de implante consistindo em aloenxerto ou colágeno e aloenxerto, método de preparação dos mesmos, uso de fosfato de cálcio poroso ou colágeno e fosfato de cálcio poroso na preparação do referido material de implante e uso de aloenxerto ou colágeno e aloenxerto na preparação do referido material de implante | |
| KR20200055149A (ko) | 척추 유합 절차를 위한 조성물 및 방법 | |
| Artzi et al. | Qualitative and quantitative expression of bovine bone mineral in experimental bone defects. Part 1: Description of a dog model and histological observations | |
| Esposito et al. | Sinus lift with guided bone regeneration or anorganic bovine bone: 1-year post-loading results of a pilot randomised clinical trial. | |
| Merli et al. | Comparing membranes and bone substitutes in a one-stage procedure for horizontal bone augmentation. Three-year post-loading results of a double-blind randomised controlled trial. | |
| Silvestri et al. | Simultaneous sinus augmentation with implant placement: histomorphometric comparison of two different grafting materials. A multicenter double-blind prospective randomized controlled clinical trial. | |
| Wiggs et al. | Oral and periodontal tissue: Maintenance, augmentation, rejuvenation, and regeneration | |
| Choi et al. | Retrospective study of maxillary sinus augmentation using demineralized tooth block bone for dental implant | |
| Al Khadher et al. | Ethoss versus mineralized plasmatic matrix for maxillary lateral sinus lifting with simultaneous implant placement | |
| AMR | “Customized Titanium Mesh versus Titanium Reinforced Membrane in localized Alveolar Ridge Augmentation with Simultaneously delayed implant placement” A randomized clinical study | |
| Urban | Guided bone regeneration: vertical growth | |
| AU2006318689B2 (en) | Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix | |
| RU40885U1 (ru) | Материал для имплантации в ткани пародонта | |
| US20240382290A1 (en) | Inner porous screw type implant | |
| MX2008006373A (en) | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix | |
| Thammanoonkul et al. | Effectiveness of polycaprolactone impregnated 3D printed hydroxyapatite in lateral maxillary sinus augmentation: a randomized controlled clinical trial | |
| Dubovina et al. | The Impact of Double Layer Membrane Technique on Bone Regeneration in Postextraction Alveoli-A Pathohistological Experimental Study in Dogs | |
| Elnakka | Cone Beam Computed Tomographic Analysis of Outcomes in Ridge Augmentation Using Titanium Mesh and Titanium Reinforced PTFE Membranes | |
| Bozidar et al. | Beta-tricalcium phosphate/type I collagen cones with or without a barrier membrane in human extraction socket healing: clinical, histologic, histomorphometric, and immunohistochemical evaluation | |
| Lopez et al. | A new technique of alveolar bone augmentation:" Pack into Bone”. A retrospective case-series study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |